New flu pill TRX-100 put to the test in human challenge trial
NCT ID NCT07503405
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a single oral dose of TRX-100 can prevent influenza infection in healthy adults aged 18 to 55. Participants will be deliberately exposed to the flu virus in a controlled setting. The trial is randomized, double-blind, and placebo-controlled, meaning neither participants nor researchers know who gets the real drug. The main goal is to see if TRX-100 reduces the number of lab-confirmed flu infections and moderate-to-severe symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tivoxavir marboxil (TRX-100)
What this could lead to
If successful, this could point toward a new oral medication to prevent influenza infection after exposure.
What could go wrong
This is an early Phase 2a proof-of-concept study with only 165 participants, so results may not apply broadly. The drug is tested in a controlled challenge model, not real-world conditions, and may fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
hVIVO Services Limited
London, E14 5NR, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••